78P Dynamic immune modulation by dendritic cell vaccination and IFN-α in advanced melanoma: Final insights from the ABSIDE phase II trial
Advanced melanoma remains a clinical challenge despite therapeutic progress. The ABSIDE trial investigated an autologous dendritic cell vaccine (DCvax) alone or in combination with radiotherapy (RT) and/or short-course IFN-α to evaluate safety, clinical activity, and immune modulation.
Authors
- J. Bulgarelli
Institutions
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2025.101163
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00